All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NPI-001
Therapeutic Area: Ophthalmology Product Name: NPI-001
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Nacuity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2021
Details:
Nanoform and Nacuity have signed a Technology Proof of Concept Agreement. This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SYL18001
Therapeutic Area: Ophthalmology Product Name: SYL18001
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
This is a Phase I clinical trial involving 36 healthy volunteers and will be carried out at the Ramón y Cajal University Hospital in Madrid (Spain). This study will evaluate the safety of SYL1801 at different doses, along with the pharmacokinetic profile of the product.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Travoprost
Therapeutic Area: Ophthalmology Product Name: OTX-TIC
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Details:
In the Phase 1 clinical trial, all cohorts experienced a mean reduction in IOP from baseline of 7-11 mm Hg of OTX-TIC with onset of action as early as two days after insertion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ONL1204
Therapeutic Area: Ophthalmology Product Name: ONL1204
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Bios Partners
Deal Size: $46.9 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 22, 2020
Details:
This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
